Corpus Striatum - Drug effects
Research News and Information

Saturday, November 21, 2009

Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor.

29 Sep 2009 The glutamate agonist LY404,039 has been used to treat schizophrenia. Because all currently used antipsychotics act on dopamine receptors, it was decided to examine whether this glutamate agonist also had an affinity for dopamine D2 receptors in ... Read more...

Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.

25 Aug 2009 We investigated the effect of early vs. late initiation of levodopa treatment on dyskinetic movements, rotational behavior and molecular markers in hemiparkinsonian rats. Male Sprague-Dawley rats received a unilateral 6-hydroxydopamine (6-OHDA) ... Read more...

Spatial discrimination reversal learning in weanling rats is impaired by striatal administration of an NMDA-receptor antagonist.

25 Aug 2009 The striatum plays a major role in both motor control and learning and memory, including executive function and "behavioral flexibility." Lesion, temporary inactivation, and infusion of an N-methyl-d-aspartate (NMDA)-receptor antagonist into the ... Read more...

Latest indexed articles for 'Corpus Striatum - Drug effects'

These are the very latest articles for this heading:

• Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor. 29 Sep 2009
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. 25 Aug 2009
• Spatial discrimination reversal learning in weanling rats is impaired by striatal administration of an NMDA-receptor antagonist. 25 Aug 2009
• Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. 20 Aug 2009
• Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. 13 Aug 2009
• Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. 11 Aug 2009
• The neurokinin-1 receptor modulates the methamphetamine-induced striatal apoptosis and nitric oxide formation in mice. 11 Aug 2009
• Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid. 11 Aug 2009
• Medical treatment of Parkinson disease. 30 Jul 2009
• Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. 30 Jul 2009
• Fast oscillations in cortical-striatal networks switch frequency following rewarding events and stimulant drugs. 29 Jul 2009
• Acquisition of and withdrawal from cocaine self-administration regulates 5-HT mRNA expression in rat striatum. 28 Jul 2009
• Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. 27 Jul 2009
• Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. 24 Jul 2009
• Cyclin-dependent kinase 5 inhibitors: inhibition of dopamine transporter activity. 21 Jul 2009
• The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices. 21 Jul 2009
• Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease. 14 Jul 2009
• The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. 13 Jul 2009
• Involvement of Basal Ganglia network in motor disabilities induced by typical antipsychotics. 7 Jul 2009
• Bilateral high frequency stimulation of the subthalamic nucleus normalizes COX activity in the substantia nigra of Parkinsonian rats. 7 Jul 2009

See a longer list of these articles.

Technical information about 'Corpus Striatum'

Definition: Striped gray and white matter consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the thalamus in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The white matter is the internal capsule.

Descriptor UI: D003342

Alternative terms: Corpus Striatum; Striatum, Corpus; Lenticular Nucleus; Nucleus, Lenticular; Nucleus Lentiformis; Lentiformis, Nucleus; Lentiform Nucleus; Nucleus, Lentiform;

Allowable Qualifiers: abnormalities; anatomy & histology; blood supply; cytology; drug effects; embryology; enzymology; growth & development; immunology; injuries; metabolism; microbiology; parasitology; pathology; physiology; physiopathology; radiation effects; radiography; radionuclide imaging; secretion; surgery; transplantation; ultrastructure; ultrasonography; chemistry; virology;

Tree Number: A08.186.211.730.885.287.249.487;

Online Note: use CORPUS STRIATUM to search LENTICULAR NUCLEUS 1974-78; use BASAL GANGLIA 1966-73

History Note: 74(72); LENTICULAR NUCLEUS was see under CORPUS STRIATUM 1974-78; was see under GANGLIA, BASAL 1963-73

Technical Notes: do not confuse with STRIATE CORTEX see VISUAL CORTEX or VENTRAL STRIATUM see BASAL GANGLIA